Andrea Bulle-Favre

Luzern, LU, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland.

Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland.

Journal: Journal of medical economics

Published: February 18, 2026

Economic burden of pulmonary arterial hypertension in Switzerland.

Economic burden of pulmonary arterial hypertension in Switzerland.

Journal: PloS one

Published: October 30, 2025

Increasing HPV vaccination coverage in Switzerland: a return-on-investment analysis.

Increasing HPV vaccination coverage in Switzerland: a return-on-investment analysis.

Journal: Journal of medical economics

Published: July 14, 2025

Health impact of using anti-PD-(L)1 agents to treat early-stage cancers in Switzerland: a modeling study.

Health impact of using anti-PD-(L)1 agents to treat early-stage cancers in Switzerland: a modeling study.

Journal: Frontiers in immunology

Published: March 28, 2025

Cost-effectiveness of pembrolizumab as an adjuvant treatment of renal cell carcinoma post-nephrectomy in Switzerland.

Cost-effectiveness of pembrolizumab as an adjuvant treatment of renal cell carcinoma post-nephrectomy in Switzerland.

Journal: Journal of medical economics

Published: October 16, 2024

Assessing the fiscal consequences of novel and existing treatments for triple negative breast cancer in Switzerland by applying a government perspective framework.

Assessing the fiscal consequences of novel and existing treatments for triple negative breast cancer in Switzerland by applying a government perspective framework.

Journal: Journal of medical economics

Published: June 21, 2024

Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.

Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.

Journal: Vaccine

Published: November 18, 2023

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland.

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland.

Journal: PharmacoEconomics - open

Published: September 14, 2023

Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland.

Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland.

Journal: Journal of medical economics

Published: February 07, 2023

Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Greece: Road to Recovery.

Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Greece: Road to Recovery.

Journal: Vaccines

Published: December 07, 2022

Understanding physician's knowledge and perception of chronic cough in Switzerland.

Understanding physician's knowledge and perception of chronic cough in Switzerland.

Journal: Current medical research and opinion

Published: April 04, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026